Diffuse non-Hodgkin's lymphoma (disorder)
REMoDL-A- A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Acalabrutinib
Year Started: 2021
The REMoDL-A clinical trial evaluates the addition of acalabrutinib to standard of care therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-Cell Lymphoma (DLBCL). As part of the study, original diagnostic FFPE tumour blocks are collected for gene expression profiling and central pathology review using IHC and FISH analysis. Tissue microarray blocks may also be produced if there is sufficient tissue left in the diagnostic FFPE tumour block. ETDA blood samples are collected at baseline before administration of any study drugs and ctDNA blood samples are also collected at 8 different timepoints throughout the study (at baseline, during trial treatment and during follow-up).
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- Outside EU access restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Imaging data | > 6 months |
Pathology records | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of urinary bladder (disorder)
BL-13
Year Started: 2019
A randomised phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Psychological data | > 6 months |
Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Suspected bladder cancer (situation)
SPIRE- A phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.
Year Started: 2016
SGI-110 is a DNA methyltransferase inhibitor developed for optimised delivery of the active metabolite decitabine. Pre-clinical data support that cisplatin resistance in bladder and other cancers is derived, at least in part, through promotor methylation of silenced genes relevant to a cisplatin resistance phenotype. Experimentally this is reversible through co-administration of DNA hypomethylating agents. The central hypothesis to be tested in this clinical trial is that SGI-110 can be safely combined with GC in bladder cancer at doses able to induce demethylation of genes associated with cisplatin resistance.
- Access:
- Open to applicants
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Diffuse large B-cell lymphoma (nodal/systemic with skin involvement) (disorder)
ACCEPT
Year Started: 2017
A Phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patient with Diffuse Large B-cell Lymphoma
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Malignant lymphoma (disorder)
RiVa
Year Started: 2017
A Phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Imaging data | > 6 months |
Pathology records | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Malignant lymphoma (disorder)
IELSG 42
Year Started: 2015
An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autologous stem cell transplant, in patients with systemic B-cell lymphoma with central nervous system involvement at diagnosis or relapse (MARIETTA regimen). This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose chemotherapy supported by ASCT.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | > 6 months |
Followup records | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
There are no material preservation details for this sample set |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
There are no material preservation details for this sample set |
Mesothelioma (malignant, clinical disorder) (disorder)
NERO
Year Started: 2022
Multicentre, 2 arm, open-label UK randomised phase II trial in Mesothelioma patients with any histological subtype and any site, who have previously received an approved systemic therapy containing platinum .
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of urinary bladder (disorder)
AURORA
Year Started: 2022
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Psychological data | > 6 months |
Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | RT | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | RT | Not applicable | 75% -99% | ||
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |